阅读说明：本技术 一种包含三种血管再生属性的混合干细胞注射液及其制备方法 (Mixed stem cell injection containing three angiogenesis attributes and preparation method thereof ) 是由 高连如 张宁坤 于 2020-04-27 设计创作，主要内容包括：本发明涉及一种包含三种血管再生属性的混合干细胞注射液,其包含华通胶间充质干细胞WJMSCs、人脐带动脉外膜周细胞APC和人脐带动脉外膜Flk-1+细胞。本发明是以新生儿遗弃的脐带为材料来源,从脐动脉外膜中提取Flk-1+细胞和脐带动脉外膜周细胞APC,这两种细胞为血管再生提供了直接的、特有的两种前体细胞,再通过WJMSCs所补充、更新及构成的新生血管的细胞外基质成分,进一步形成血管再生信号系统调控下血管前体细胞向血管分化的再生微环境。将这三种干细胞按比例混合进行体外培养实验,结果证实在体外培养13天后成功形成了血管网。本发明的注射液可制成用于血管再生的注射剂,用于治疗缺血性心脏病、缺血性脑卒中、缺血性周围血管病等疾病。(The invention relates to a mixed stem cell injection containing three angiogenesis attributes, which comprises Wharton jelly mesenchymal stem cells WJMSCs, human umbilical artery adventitia pericytes APC and human umbilical artery adventitia Flk-1+ cells. The invention takes the abandoned umbilical cord of the newborn as a material source, Flk-1+ cells and umbilical cord artery adventitia pericyte APC are extracted from the umbilical artery adventitia, the two cells provide two direct and specific precursor cells for the regeneration of blood vessels, and then the regeneration microenvironment for the differentiation of the blood vessel precursor cells to the blood vessels under the regulation and control of a blood vessel regeneration signal system is further formed through the extracellular matrix components of the new blood vessels supplemented, updated and formed by WJMSCs. The three stem cells are mixed in proportion to carry out in vitro culture experiments, and the result proves that the vascular network is successfully formed after in vitro culture for 13 days. The injection can be prepared into injections for revascularization, and is used for treating diseases such as ischemic heart disease, ischemic stroke, ischemic peripheral vascular disease and the like.)

1. A mixed stem cell injection comprising three angiogenic properties, comprising: wharton jelly mesenchymal stem cells WJMSCs, human umbilical artery adventitia pericytes APC and human umbilical artery adventitia Flk-1+ cells.

2. The injection according to claim 1, wherein the human umbilical cord artery adventitia pericyte APC, the human umbilical cord artery adventitia Flk-1+ cell and the Wharton's jelly mesenchymal stem cell WJMSCs are mixed according to the cell number ratio of 1:40-60: 80-120.

3. The injection according to claim 1 or 2, wherein the injection further comprises human serum albumin, and the mass concentration of the human serum albumin in the injection is 0.2-0.25%.

4. The injection of claim 1, wherein the injection has a size of 2 mL/tube and a total cell number of 1.5 × 10 per tube⁷～2.5×10⁷。

5. A preparation method of a mixed stem cell injection containing three angiogenesis attributes comprises the following steps:

s1, preparing human umbilical cord artery adventitia Flk-1+ cells;

s2, preparing human umbilical cord artery adventitia pericyte APC;

s3, extracting and culturing WJMSCs from the Huatong glue source mesenchymal stem cells;

s4, mixing the human umbilical artery adventitia pericyte APC, the human umbilical artery adventitia Flk-1+ cells and the Wharton jelly mesenchymal stem cells WJMSCs in proportion, and preparing the mixture into injection by using water for injection or normal saline.

6. The preparation method according to claim 5, wherein in step S4, the human umbilical artery adventitia pericyte APC, the human umbilical artery adventitia Flk-1+ cell and the Wharton' S jelly mesenchymal stem cell WJMSCs are mixed according to a cell number ratio of 1:40-60: 80-120.

7. The method according to claim 5, wherein in step S4, the hypoxia-cultured second or third generation human umbilical cord artery adventitia pericytes APC, human umbilical cord artery adventitia Flk-1+ cells and WJMSCs are added with physiological saline, respectively, the cells are centrifugally washed at a centrifugal force of (100) -200 g, the supernatant is discarded, the cells are washed 2-4 times, and the three cells are prepared with physiological saline to 1.5 × 10 cells/ml, respectively⁷～2.5×10⁷Mixing the three cell suspensions according to the proportion of the number of the three cells, and supplementing the three cell suspensions to a preset injection specification by using physiological saline; sealing, and using immediately, or storing at 4-8 deg.C for 12 hr.

8. The method according to claim 5 or 6, wherein in step S4, human serum albumin is further added when preparing the injection, wherein the human serum albumin has a mass concentration of 0.2% -0.25%, and is prepared into 2mL per tube containing 1.5 × 10⁷～2.5×10⁷The cell number is one unit of injection.

9. The production method according to any one of claims 5 to 7,

step S1 includes the following steps performed in order: extracting and purifying human umbilical artery adventitia Flk-1+ cells, carrying out 3D culture, carrying out 3D subculture and carrying out hypoxia culture; wherein, the human umbilical artery adventitia Flk-1+ cells are extracted from the fresh umbilical cord of a newborn, and the human umbilical artery adventitia Flk-1+ cells used for preparing the injection are Flk-1+ cells after completing hypoxic culture;

step S2 includes the following steps performed in order:

extracting and purifying human umbilical artery adventitia pericyte APC, carrying out 3D culture, carrying out 3D subculture and carrying out hypoxia culture; wherein, the human umbilical cord artery adventitia pericyte APC is extracted from a fresh umbilical cord of a newborn, and the human umbilical cord artery adventitia pericyte APC used for preparing the injection is a CD140 and CD146 double-positive cell after completing the hypoxic culture;

step S3 includes the following steps performed in order: extracting, purifying, 3D culturing, 3D subculturing and hypoxia culturing WJMSCs, wherein the WJMSCs are extracted from Wharton jelly tissues among fresh umbilical cord arteries, umbilical veins and umbilical cord adventitia of a newborn, and WJMSCs cells used for preparing injection are second or third generation WJMSCs after the hypoxia culturing is finished.

10. The method according to claim 9, wherein the steps S1, S2, and S3 further comprise a step of freezing the cells, i.e., the cells after completion of the hypoxic culture are washed and then mixed well with a complete cell culture medium containing 8-12% DMSO at a cell concentration of 1.5 × 10⁷～2.5×10⁷and/mL, cooling at the speed of 0.5-1.5 ℃/min by using a programmed cooling instrument, and when the temperature is reduced to-80 ℃, putting the cells into liquid nitrogen for freezing and storing for use when needed.

Technical Field

The invention relates to the technical field of biomedical materials, in particular to an injection containing stem cells with various angiogenesis attributes and a preparation method thereof.

Background

Ischemic diseases caused by vascular disorders such as: coronary heart disease, cerebral infarction, limb ischemic necrosis, even ischemic blindness of the eye …, and the like, are the first causes of death and disability in the world so far. Modern medicine cannot fundamentally improve the prognosis of the disease with medicines, interventions, operations and organ transplantation. Although the stem cell regeneration medicine of the 21 st century brings a new machine, the specificity, functionality and safety of the seed cell regenerated blood vessel greatly restrict the realization of the stem cell regenerated blood vessel idea.

At present, although the Embryonic Stem Cells (ESC) and the induced pluripotent stem cells (iPS) with full differentiation potential can regenerate blood vessels, the ESC relates to ethics and teratoma, and the iPS relates to the tumor risk, so that the ESC and the iPS cannot be clinically used. Adult stem cells, including mesenchymal stem cells of different origin, can only stimulate angiogenesis limitedly by paracrine/autocrine potential. Because of the current research, any adult cell such as CD133, CD34, mesenchymal stem cell and the like can not regenerate to form blood vessel with blood perfusion function.

Related studies have found that the adventitia is a reservoir precursor cell nest (niche). Periarterial adventitial cells (Pericytes) are key cells for angiogenesis, development, regeneration, stabilization of vascular structure, regulation of blood flow, and regulation of local immune function; the Flk-1+ cells (vascular endothelial growth factor receptor positive cells) of the adventitia are blood vessel and cardiac muscle precursor cells, and directly participate in and regulate angiogenesis and regeneration; the Huatong glue source mesenchymal stem cells (WJMSCs) have the paracrine/autocrine function of promoting the regeneration of blood vessels, secrete various cell factors such as vascular endothelial growth factors, fibroblast growth factors, hepatocyte growth factors … and the like, and directly participate in the construction of the components of the vascular regeneration matrix.

In 2018, Spain Dr. Alvino firstly applied the remaining great saphenous vein of a coronary heart disease bypass patient to separate and culture periadventitial cells of a blood vessel, and the periadventitial cells are transplanted to a pig myocardial infarction model, so that perfusion of the blood vessel and the myocardium is increased. However, only the use of patient blood vessels as a source for pericyte extraction has been proposed internationally. However, it is obvious that it is very difficult, invasive and difficult to popularize to draw materials from the extravascular membrane of a patient.

Disclosure of Invention

Technical problem to be solved

In order to solve the above problems in the prior art, the present invention provides a mixed stem cell injection containing three angiogenesis attributes and a preparation method thereof, wherein the three angiogenesis attributes stem cells are human umbilical cord artery Adventitia Pericytes (APC), human umbilical cord artery adventitia Flk-1+ cells and huatong glue mesenchymal stem cells (WJMSCs), wherein the APC and Flk-1+ cells are extracted from the umbilical artery adventitia of a newborn baby, and two specific precursor cells are directly provided for angiogenesis; WJMSCs are derived from Wharton jelly tissues among umbilical arteries, umbilical veins and umbilical cord adventitia, are used for supplementing, updating and forming extracellular matrix components of new vessels, and further provide a regeneration microenvironment for differentiation of blood vessel precursor cells to blood vessels under the regulation and control of a blood vessel regeneration signal system.

The injection can promote arterioles/capillaries with the function of transmitting blood, not only realizes the function of regenerating blood vessels which can be achieved by embryonic stem cells, induced pluripotent stem cells and the like, but also avoids the defects that ESC and iPS are difficult to apply to clinic.

(II) technical scheme

In order to achieve the purpose, the invention adopts the main technical scheme that:

in one aspect, the present invention provides a mixed stem cell injection comprising three angiogenic properties, comprising: wharton jelly mesenchymal stem cells WJMSCs, human umbilical artery adventitia pericytes APC and human umbilical artery adventitia Flk-1+ cells.

According to a preferred embodiment of the present invention, the injection further comprises a physiological saline, and the physiological saline is a solvent of the injection.

According to the preferred embodiment of the invention, in the injection, the human umbilical artery adventitia pericyte APC, the human umbilical artery adventitia Flk-1+ cell and the Wharton's jelly mesenchymal stem cell WJMSCs are mixed according to the cell number ratio of 1:40-60: 80-120.

Preferably, the human umbilical cord artery adventitia pericyte APC, the human umbilical cord artery adventitia Flk-1+ cell and the Wharton jelly mesenchymal stem cell WJMSCs are mixed according to the cell number ratio of 1:50: 100.

According to a preferred embodiment of the invention, the injection also contains human serum albumin, and the mass concentration of the human serum albumin in the injection is 0.2-0.25%.

According to the preferred embodiment of the present invention, the specification of the injection is 2 mL/tube, and the total number of cells in each tube is (1.5-2.5) × 10⁷。

In another aspect, the present invention provides a method for preparing a mixed stem cell injection solution containing three angiogenesis attributes, which comprises the following steps:

s1, preparing human umbilical cord artery adventitia Flk-1+ cells;

s2, preparing human umbilical cord artery adventitia pericyte APC;

s3, extracting and culturing WJMSCs from the Huatong glue source mesenchymal stem cells;

s4, mixing the human umbilical artery adventitia pericyte APC, the human umbilical artery adventitia Flk-1+ cells and the Wharton jelly mesenchymal stem cells WJMSCs in proportion, and preparing the mixture into injection by using water for injection or normal saline.

It should be noted that the sequence of steps S1-S3 is not limited, as long as the preparation of Flk-1+ cells, pericytes APC, Wharton jelly mesenchymal stem cells WJMSCs is completed.

According to a preferred embodiment of the present invention, wherein: in step S4, the human umbilical cord artery adventitia pericyte APC, the human umbilical cord artery adventitia Flk-1+ cell and the Huatong glue mesenchymal stem cell WJMSCs are mixed according to the cell number ratio of 1:40-60:80-120, preferably 1:50: 100.

According to a preferred embodiment of the present invention, in step S4, the hypoxia-cultured second or third generation human umbilical cord artery pericyte APC, human umbilical cord artery pericyte Flk-1+ cells, WJMSCs are added with physiological saline respectively, the cells are washed by centrifugation at a centrifugal force of 200 g (100-⁷Cell suspension with concentration, and three cell numbersMixing the three cell suspensions, and supplementing to a predetermined injection specification by using normal saline; sealing, and using immediately, or storing at 4-8 deg.C for 12 hr.

According to the preferred embodiment of the present invention, the total number of cells per tube is (1.5-2.5) × 10⁷In general, when cells are used, the amount of 6 × 10 is 60 kg per body weight of the human⁷2 × 10 per tube⁷The number of cells was exactly three tubes, and the number of cells used was easily increased or decreased according to the increase or decrease of body weight, and the syringe was used to smoothly draw the cells, about 2 × 10⁷The number of cells in the volume of about 2mL is proper, and the use and the operation are inconvenient because the cell concentration is too high or too low.

According to the preferred embodiment of the present invention, in step S4, human serum albumin is further added when preparing the injection, wherein the human serum albumin has a mass concentration of 0.2% -0.25%, and is prepared to contain (1.5-2.5) × 10 per 2mL⁷The cell number is one unit of injection. The human serum albumin is added to ensure the charge balance among cells and prevent the aggregation of the cells, and the human serum albumin is added to provide proper nutrition for the cells in the physiological saline and maintain the activity of the cells.

According to a preferred embodiment of the present invention, wherein: step S1 includes the following steps performed in order: extracting and purifying human umbilical artery adventitia Flk-1+ cells, carrying out 3D culture, carrying out 3D subculture and carrying out hypoxia culture; wherein, the human umbilical artery adventitia Flk-1+ cells are extracted from the fresh umbilical cord of a newborn, and the human umbilical artery adventitia Flk-1+ cells used for preparing the injection are Flk-1+ cells after completing hypoxic culture.

According to a preferred embodiment of the present invention, wherein: step S2 includes the following steps performed in order: extracting and purifying human umbilical artery adventitia pericyte APC, carrying out 3D culture, carrying out 3D subculture and carrying out hypoxia culture; wherein, the human umbilical cord artery adventitia pericyte APC is extracted from a newborn fresh umbilical cord, and the human umbilical cord artery adventitia pericyte APC used for preparing the injection is a CD140 and CD146 double-positive cell after completing the hypoxic culture.

According to a preferred embodiment of the present invention, wherein: step S3 includes the following steps performed in order: extracting, purifying, 3D culturing, 3D subculturing and hypoxia culturing WJMSCs, wherein the WJMSCs are extracted from fresh umbilical cords of newborn infants, and the WJMSCs used for preparing injection are second or third generation WJMSCs after the hypoxia culturing is finished.

According to a preferred embodiment of the present invention, the steps S1-S3 further comprise freezing the cells, i.e., the cells after completion of the hypoxic culture are washed and then mixed with a complete cell culture medium containing 8-12% DMSO to obtain a cell concentration of (1.5-2.5) × 10⁷and/mL, cooling at the speed of 0.5-1.5 ℃/min by using a programmed cooling instrument, and putting the cells into liquid nitrogen for freezing when the temperature is reduced to-80 ℃.

(III) advantageous effects

The beneficial effects of the invention comprise the following points:

(1) in the injection, cells with three angiogenesis attributes are all obtained from umbilical cords abandoned by newborns, specifically, umbilical cord artery adventitia Flk-1+ cells and umbilical cord artery Adventitia Pericytes (APC) are extracted from two arteries in the umbilical cords of the newborns, and the two cells provide two direct and specific precursor cells for angiogenesis; in addition, the injection also comprises Wharton jelly mesenchymal stem cells (WJMSCs, which are obtained from Wharton jelly tissues among umbilical arteries, umbilical veins and the umbilical cord adventitia) extracted from the umbilical cord of the newborn, and extracellular matrix components of the newborn blood vessel are supplemented, updated and formed by the WJMSCs, so that a regeneration microenvironment for differentiating the blood vessel precursor cells into blood vessels under the regulation of a blood vessel regeneration signal system is further formed: the endothelial cells are used as the vascular intima, the pericytes APC are inserted into the periphery of the endothelial cells and integrated with the endothelial cells, and the endothelial cells, the Flk-1+ cell differentiated outer basement membrane and smooth muscle cells derived from the pericytes APC are formed to jointly form arterioles/capillaries with the function of transmitting blood.

(2) The mixed stem cell injection containing the three angiogenesis attributes not only realizes the angiogenesis regeneration function which can be achieved by embryonic stem cells, induced pluripotent stem cells and the like, but also avoids the defects that ESC and iPS are difficult to apply to clinic.

(3) The stem cells with three angiogenesis attributes are selected for the first time to jointly form a cell mixed solution, and the effect of angiogenesis can be successfully achieved only by totipotent and sub-totipotent stem cells such as ESC and iPS; overcomes the defect that ESC and iPS can not be used clinically.

(4) The invention breaks through the obstacle that the existing adult stem cells can not be successfully differentiated to form small blood vessels with the function of blood perfusion for the first time, and avoids the problems of difficult and invasive material taking of autologous veins of peripheral cells of the umbilical cord artery adventitia; the vascular differentiation microenvironment based on WJMSCs with significant paracrine/autocrine function was created for the first time for vascular differentiation precursor cells.

(5) The injection of the invention has the quantity ratio of APC, Flk-1+ cells of human umbilical cord adventitia and WJMSCs of 1:40-60:80-120, and is mainly designed according to the position characteristics of pericytes, Flk-1+ cells and WJMSCs in human anatomy and special physiological functions. The anatomic pericyte APC exists around the endothelial cell, and the density, morphology, biology and other aspects of the pericyte APC are different in different organs according to the strictness of the requirement of the endothelial barrier, and the proportion of the pericyte APC to the endothelial cell is also different strictly. For example, the ratio of pericytes to endothelial cells is 1:100 in skeletal muscle, 1:3 in the nervous system and 1:1 in the retina. Based on this feature, the present invention experimentally determined that the ratio of pericytes to Flk-1+ cells is about 1:50 to be most suitable for regenerating blood vessels of a plurality of organs. While WJMSCs mainly play a role in providing a microenvironment for differentiation/regeneration of pericyte APC and Flk-1+ cells, and the cell number ratio of the WJMSCs is relatively larger. Therefore, the invention mixes the three cells according to the biological function requirement in a quantity ratio of 1:40-60:80-120, and preferably mixes the three cells in a quantity ratio of 1:50:100 to prepare the injection.

(6) The invention successfully separates high-purity pericytes and Flk1+ cells from the umbilical artery adventitia, and the cell activity and differentiation potential (0.81 plus or minus 0.07, MTT method OD value) and proliferation power (0.76 plus or minus 0.08, 24h proliferation power, MTT method OD value) of the high-purity pericytes and Flk-1+ cells are far stronger than autologous great saphenous vein derived pericytes and bone marrow derived Flk-1+ cells.

According to the experimental verification, the angiogenesis mixed stem cell injection provided by the invention successfully forms a vascular network after in vitro culture for 13 days; successfully forms small blood vessels consisting of endothelial cells, pericytes, basement membrane and smooth muscle cells.

(7) APC, Flk-1+ cells from umbilical artery adventitia and WJMSCs from Wharton's jelly all only express HLA-ABC, do not express HLA-II-class antigen HLA-DR, and because of co-stimulating antigen CD80 and CD86 to express HLA-G, the product has low immunogenicity, small rejection reaction, and can be used for variant application, large-scale preparation and preparation into biological ' injection medicine ' for popularization and application.

Drawings

FIG. 1 is a picture of the morphology of Flk-1+ cells of the umbilical cord artery adventitia extracted and purified by the present invention.

FIGS. 2A-2B show the expression of specific markers of Flk-1+ cells extracted and purified from the umbilical cord artery adventitia according to the invention.

FIG. 3 is a picture of the APC morphology of cord artery periadventitial cells extracted and purified according to the present invention.

FIGS. 4A-4B show the expression of specific markers of APC extracted and purified periadventitial cells of umbilical cord artery according to the present invention.

FIG. 5 is an inverted microscope photograph of a vascular network formed by mixed culture of three cells of APC, Flk-1+ and WJMSCs in a cell number ratio of 1:50:100 in example 1.

FIG. 6 shows the specific expression of the vascular endothelial cell marker CD31+ cells of FIG. 5.

FIG. 7 is an inverted microscope photograph of a vascular network formed by mixed culture of three cells of APC, Flk-1+ and WJMSCs in a cell number ratio of 1:50:100 in example 1.

FIG. 8 shows the specific expression of the vascular endothelial cell marker CD31+ cells of FIG. 7.

Detailed Description

For the purpose of better explaining the present invention and to facilitate understanding, the present invention will be described in detail by way of specific embodiments with reference to the accompanying drawings.

The invention has the following overall technical scheme conception:

taking umbilical cord abandoned by a newborn as a material source, extracting Flk-1+ cells and APC (extracellular plasma-activated plasma) of umbilical artery adventitia periadventitia cells from the umbilical artery adventitia, extracting WJMSCs (WJMSCs) from Wharton jelly tissues among umbilical artery, umbilical vein and umbilical cord adventitia, and mixing the three stem cells in proportion to prepare an injection for blood vessel regeneration, which is used for treating diseases such as ischemic heart disease, ischemic stroke, ischemic peripheral vascular disease and the like.

In order to prepare the mixed stem cell injection containing the three angiogenesis attributes, three stem cells need to be prepared in advance, and finally, the three stem cells are respectively dispersed in physiological saline to prepare the injection. The three stem cells were prepared as follows:

the preparation method of the umbilical cord artery adventitia Flk-1+ cells comprises the following steps:

extracting human umbilical artery adventitia Flk-1+ cells: taking a fresh umbilical cord, rinsing by PBS, washing off residual blood of the umbilical cord, cutting off Huatong glue along the trend of the umbilical artery, cutting off the umbilical artery longitudinally along the cavity of the umbilical artery, wherein the cross section is only two layers from outside to inside, namely an outer membrane and an inner membrane respectively, tearing off the inner membrane at the cut section of the umbilical artery by using a pair of toothed tweezers, tearing off the outer membrane of the umbilical artery, and putting the torn umbilical artery outer membrane in a sterile vessel to be cut into a foam shape as fine as possible.

And (3) putting the stripped umbilical artery adventitia fragments into a sterile cell culture bottle, adding a serum-free cell culture medium into the culture bottle, and putting the culture bottle into a culture box with the temperature of 36-37 ℃, the volume concentration of 5% of carbon dioxide and the saturated humidity for culture. And after the cells adhere to the wall, replacing the culture medium in the cell culture bottle with an improved Endothelial Cell (EC) growth culture medium, replacing the cell culture medium every 2-5 days, and observing the cell growth condition under a microscope until the cells are more than 80% of the bottle bottom.

Purifying Flk-1+ cells:

preparing a single cell suspension: abandoning the culture medium in the cell culture bottle, adding PBS to wash the bottom of the bottle, abandoning the washing liquid, adding trypsin with the concentration of 0.08-0.15 percent, and uniformly paving the bottom of the bottle, thereby being a cell digestion step; after 1-2 minutes, the cells can be seen to shrink under a microscope, a cell culture medium is added to stop digestion, a pipette is used for sucking and blowing the cell suspension, and the cell suspension is uniformly mixed to prepare the cells into single cell suspension.

And (3) washing the cells: transferring the single cell suspension into a centrifuge tube, adding PBS for uniformly mixing, centrifuging for 10-20min at (100-.

Sorting, after discarding the supernatant, adding cell sorting buffer solution to adjust the cell concentration to 2 × 10⁷Per mL, add anti-Flk 1, CD34 antibody, every 1 × 10⁶Adding 0.25 μ g of cells, incubating at 4 deg.C for 30min, adding 20 times of volume selection buffer, centrifuging for 4-10 min, washing with 300g of selection buffer, discarding supernatant, adding selection buffer, mixing cells, and adjusting cell concentration to 2 × 10⁷Adding secondary antibody coated magnetic beads, each 1 × 10⁶Adding 5 mu L of secondary antibody coated magnetic beads into cells, incubating at 8-15 ℃ for 10-15min, adding 20 times of volume sorting buffer solution, centrifugally washing 300g, discarding supernatant, adding sorting buffer solution, mixing to obtain cell suspension, and adding 500 mu L/10 of sorting buffer solution⁸(ii) individual cells; washing the separation column with a buffer solution in advance, mounting the column in a magnetic field, adding the cell suspension into the column, washing the column with the buffer solution for three times, removing the column from the magnetic field, putting the column into a new centrifuge tube, washing the centrifuge tube with a small amount of buffer solution forcibly, washing the cells in the centrifuge tube, and collecting the cells, namely Flk-1+ umbilical artery adventitial cells.

③ 3D culture, adding Flk-1+ cells into hydrogel culture medium, mixing to make cell concentration (0.8-1) × 10⁵cells/mL, which is a hydrogel cell suspension, were added to new flasks such that each flask was seeded with a cell number of (0.8-1) × 10⁶Adding a cross-linking agent into a culture bottle to promote hydrogel to form a jelly-like shape, adding 5mL of complete cell culture medium on the surface of the hydrogel liquid in the culture bottle, placing the culture bottle containing the aqueous gel cell suspension in a culture box with the temperature of 36-37 ℃, the volume concentration of carbon dioxide and the saturation humidity, performing amplification culture, and observing the growth condition of the cells every day.

④ 3D subculture, after 3D culture for 6-7 days, adding PBS10mL at 36-37 ℃ when cell fusion is 70-80%, placing in water bath at 36-37 ℃ until hydrogel is decomposed to form cell suspension, sucking with a pipette, mixing cell suspension, transferring the suspension into a centrifuge tube, (100-) g, centrifuging for 10-20min by centrifugal force, removing supernatant, adding hydrogel, mixing, adding into culture bottle to make the cell number in each culture bottle be (0.8-1) × 10⁶Adding 0.1mL of cross-linking agent into a culture bottle to promote hydrogel to form a jelly shape, adding a serum-free culture medium on the liquid level of the hydrogel in the culture bottle, placing the culture bottle containing aqueous gel cell suspension in a culture box with the temperature of 36-37 ℃, the volume concentration of 5% of carbon dioxide and the saturation humidity for amplification culture for 6-7 days, observing the growth condition of the cells every day, and taking the second and third-generation Flk-1+ cells to enter the next procedure.

⑤ hypoxic culture, washing second generation Flk-1+ cells, adding complete cell culture medium, adjusting cell concentration to (0.8-1) × 10⁵10mL of the suspension was added to a cell culture flask, and the total number of cells was (0.8-1) x10⁶Firstly, a cell culture bottle is put into a carbon dioxide saturated humidity incubator with the volume fraction of 5 percent at 37 ℃ for culture, when the cell adherent culture is up to 60 percent fusion, the cell culture bottle is put into a hypoxia incubator with the oxygen volume concentration of 5 percent at 37 ℃ and the saturated humidity for culture for 12 hours, and the next procedure is carried out after washing. By the low-oxygen culture, the cell tolerance, activity and viability are improved.

The Flk-1+ cells can then be used to prepare injections, which are frozen for use if not used.

⑥ freezing and storing the second or third generation cells, washing, adding into complete cell culture medium containing 8-12% DMSO, and mixing to make cell concentration (1.5-2.5) × 10⁷and/mL, cooling at the speed of 0.5-1.5 ℃/min by using a programmed cooling instrument, and when the temperature is reduced to-80 ℃, putting the cells into liquid nitrogen for freezing storage for resuscitation culture and use when required.

(II) a preparation method of human umbilical cord artery adventitia pericyte APC, which comprises the following steps:

extracting human umbilical artery adventitia pericyte APC: taking a fresh umbilical cord produced by caesarean section, rinsing with PBS for 2-4 times, washing off residual blood of the umbilical cord, washing off the residual blood, cutting the umbilical cord into small sections, cutting the umbilical cord along the direction of umbilical artery, clamping one end of the umbilical artery with a toothed forceps, tearing off two external umbilical artery membrane layers, tearing off the external umbilical artery membrane layers, putting the umbilical artery membrane layers into a sterile flat dish, and rinsing with PBS for 2-4 times the external umbilical artery membrane layers torn off from the umbilical artery.

Transferring the torn umbilical artery adventitia into a centrifuge tube, adding type II collagenase with the volume 5 times more than that of the umbilical artery intima and the concentration of 0.2-0.25%, sealing the centrifuge tube, placing the centrifuge tube into a water bath, and adjusting the temperature of the water bath to 36-37 ℃, wherein the step is digestion; after digesting for 60-90 minutes, adding a serum-free culture medium with the same volume as the digestive juice in the centrifuge tube, fully and uniformly mixing by using a pipette, centrifuging for 8-20 minutes at (100-; repeating the washing steps, washing the cells for 2-4 times, removing the supernatant, adding a serum-free culture medium, fully mixing to form a cell suspension, taking a new centrifuge tube, placing a 70-micrometer filter at a tube opening, and filtering the cells into the new centrifuge tube by the cell suspension through the filter.

Counting cells in the filtered cell suspension, and preparing the cell suspension (0.8-1) × 10 with serum-free medium⁵At a concentration of 10mL, 10mL of the cell suspension was added to a cell culture flask, and serum-free medium was added to the flask so that the total amount of the liquid in the flask was 15mL and the total number of cells was (0.8-1) × 10⁶Placing the cell culture bottle at 36-37 deg.C and 5% CO₂And in a cell culture box with saturated humidity, observing cells every day, replacing the culture medium in a cell culture bottle by half every three days, and entering the next procedure when the cell fusion degree reaches more than 90%.

② purifying the APC of the pericytes:

preparing a single cell suspension: discarding the culture medium in the cell culture bottle, adding PBS to wash the bottom of the bottle, discarding the washing liquid, adding 0.08% -0.15% trypsin, and uniformly spreading the trypsin on the bottom of the bottle, which is the step of digesting the cells; standing for 1-2 min, adding serum-free culture medium to stop digestion reaction when the cells are seen to shrink into round shape under microscope, sucking and blowing the cell suspension by a pipette, and mixing uniformly to prepare the cells into single cell suspension.

And (3) washing the cells: transferring the single cell suspension into a centrifuge tube, adding PBS for uniformly mixing, centrifuging for 10-20min at (100-.

Sorting, discarding supernatant, adding cell sorting buffer solution, adjusting cell concentration to 2 × 10⁷Per mL, add anti-CD 140, CD146 antibodies, every 1 × 10⁶Adding 0.25 μ g of cells, incubating at 4 deg.C for 30min, adding 20 times of volume selection buffer, centrifuging for 5-10 min, discarding supernatant, adding selection buffer, mixing cells, and adjusting cell concentration to 2 × 10⁷Per mL, add secondary antibody-coated magnetic beads, every 1 × 10⁶Adding 5 μ L of secondary antibody-coated magnetic beads into the cells, and incubating at 8-15 deg.C for 10-15 min; adding 20 times of volume selection buffer solution, centrifuging for 7 minutes at 300g, washing, discarding supernatant, adding the selection buffer solution, mixing cells, and adding the selection buffer solution at 500 μ L/10⁸Washing the separation column with a buffer solution in advance, installing the column into a magnetic field, adding the cell suspension into the column, washing the column with the buffer solution for three times, removing the column from the magnetic field to a new centrifuge tube, washing the centrifuge tube with a small amount of buffer solution forcibly, and washing the cells in the centrifuge tube to obtain the collected cells, namely CD140+, CD146+ periumbilical cord artery adventitial cells (APC).

③ culturing CD140+ and CD146+ cells in 3D culture by centrifuging CD140+ and CD146+ cell suspension (100-⁵Cells, which are hydrogel cell suspensions, were added to new cell culture flasks with 10mL of hydrogel cell suspension, each flask being seeded with a cell number of (0.8-1) × 10⁶Adding 0.1mL of cross-linking agent into a culture bottle to promote hydrogel to form a jelly-like shape, adding 5mL of complete cell culture medium on the surface of the hydrogel in the culture bottle, placing the culture bottle containing the aqueous gel cell suspension in a culture box with the temperature of 36-37 ℃, the volume fraction of carbon dioxide and the saturation humidity for amplification culture, and observing the growth condition of the cells every day.

④ CD140+ and CD146+ cells for 3D subculture, after 3D culture for 6-7 days, adding 70-80% of PBS at 36-37 ℃ when cell fusion occurs, placing in water bath at 36-37 ℃, decomposing hydrogel after 40-60min to form cell suspension, sucking and uniformly mixing the cell suspension by using a pipette, transferring the suspension into a centrifuge tube, centrifuging by using (100-Homogenizing, adding into cell culture flask to obtain cell number of (0.8-1) × 10⁶Adding 0.1mL of cross-linking agent into a culture bottle to promote hydrogel to form a jelly shape, adding 5mL of serum-free culture medium on the surface of the hydrogel in the culture bottle, placing the culture bottle containing the aqueous gel cell suspension in an incubator with carbon dioxide and saturated humidity at the temperature of 36-37 ℃ and the volume concentration of 5% for amplification culture for 6-7 days, observing the growth condition of the cells every day, and taking the second-generation CD140 and CD146 double-positive cells (considered as pericyte APC) to enter the next process.

⑤ hypoxia culturing, washing the second generation cell, adding serum-free cell culture medium, and adjusting cell concentration to (0.8-1) × 10⁵10mL of the suspension was added to a cell culture flask, and the total number of cells was (0.8-1) × 10⁶Firstly, placing a cell culture bottle into a carbon dioxide saturated humidity incubator with the volume fraction of 5% at 37 ℃ for culture, placing the cell culture bottle into a hypoxia incubator with the oxygen volume concentration of 5% and the saturated humidity at 37 ℃ for culture for 12 hours after 60% fusion of adherent culture of cells, and washing and entering the next procedure. By the low-oxygen culture, the cell tolerance, activity and viability are improved.

The CD140 and CD146 double positive cells (namely the pericyte APC) can be used for preparing injection, and the injection is frozen and stored for later use if not used.

⑥ freezing and storing the second or third generation of well-grown cells, washing, adding into serum-free cell culture medium containing 8-12% DMSO, and mixing to make the cell concentration (1.5-2.5) × 10⁷and/mL, cooling at the speed of 0.5-1.5 ℃/min by using a programmed cooling instrument, and when the temperature is reduced to-80 ℃, putting the cells into liquid nitrogen for freezing storage for resuscitation culture and use when required.

(III) extracting and culturing human umbilical Wharton jelly source mesenchymal stem cells (WJMSCs), wherein the process comprises the following steps:

extracting human umbilical cord Wharton jelly source mesenchymal stem cells (WJMSCs): taking a fresh human umbilical cord, washing off residual blood of the umbilical cord by using an isotonic balanced salt solution, cutting the umbilical cord into small sections, cutting off each section of the umbilical cord along an umbilical vein cavity, washing off the residual blood in the vein cavity by using the isotonic balanced salt solution, flatly paving the umbilical cord in a sterile dish, removing umbilical arteries, umbilical veins and an umbilical cord adventitia, extracting a Wharton jelly tissue among the umbilical arteries, the umbilical veins and the umbilical cord adventitia, cutting the Wharton jelly tissue into blocks with the size of 1 cubic millimeter or less, and cleaning the Wharton jelly tissue cut into blocks by using the isotonic balanced salt solution.

Extracting and culturing the Huatong glue mesenchymal stem cells: adding 10mL of serum-free culture medium into a culture bottle, uniformly placing the tissue cut into blocks in the culture bottle, placing the culture bottle with the tissue in the culture bottle at 36-37 deg.C and 5% CO₂Culturing in a saturated humidity incubator, changing liquid for half 3 days, observing adherent growth of mesenchymal stem cells in 5-6 days, fusing the Wharton jelly mesenchymal stem cells growing adherent in 10-12 days to more than 80%, and entering the next procedure.

② purification

Preparing a single cell suspension: discarding the culture medium in the cell culture bottle, adding PBS to wash the bottom of the bottle, discarding the washing liquid, adding trypsin with the concentration of 0.08% -0.15%, uniformly spreading the trypsin on the bottom of the bottle for digestion, observing cell shrinkage under a microscope after 1-2 minutes, adding 3mL of cell culture medium to stop digestion, sucking and blowing the cell suspension by a pipettor, and uniformly mixing, thus preparing the cells into single cell suspension.

Washing: the cell suspension is transferred to a 50mL centrifuge tube through a 100 μm screen, 20mL PBS is added for even mixing, centrifugation is carried out for 10min at (100-.

Passage, adding serum-free culture medium, regulating cell concentration to (0.8-1) × 10⁵Perml, the cell suspension was added to the cell culture flask so that the number of cells per flask was (0.8-1) × 10⁶And (3) cells, wherein the step is passage, the passage cells are placed in an incubator with the temperature of 36-37 ℃, the volume concentration of carbon dioxide and the saturated humidity of 5% for amplification culture, the liquid is changed every three days, and the passage culture is carried out when the cells are fused to 80-90%, so as to enter the next procedure (or be used for preparing injection immediately).

③ 3D culture of WJMSCs by centrifuging the second generation WJMSCs cell suspension at (100-200) g for 10-20min, discarding the supernatant, adding hydrogel culture medium, and mixing to obtain fine cellsThe cell concentration is (0.8-1) × 10⁵cells/mL, which is a hydrogel cell suspension, 10mL of hydrogel cell suspension was added to a fresh flask, and the number of cells seeded in each flask was (0.8-1) × 10⁶Adding 0.1mL of cross-linking agent into a culture bottle to promote hydrogel to form a jelly-like shape, adding 5mL of complete cell culture medium on the surface of the hydrogel in the culture bottle, placing the culture bottle containing the aqueous gel cell suspension in a culture box with the temperature of 36-37 ℃ and the volume concentration of 5% of carbon dioxide and the saturation humidity for amplification culture, and observing the growth condition of the cells every day.

④ 3D subculture of WJMSCs, adding PBS10mL at 36-37 ℃ when cell fusion is 70-80% after 3D culture for 6-7 days, placing in water bath at 36-37 ℃, decomposing hydrogel to form cell suspension after 40-70min, sucking and uniformly mixing the cell suspension by using a pipette, transferring the suspension into a 50mL centrifuge tube, centrifuging by 10m-20in (100-200) g of centrifugal force, removing supernatant, adding hydrogel, uniformly mixing, and adding into a cell culture bottle to ensure that the number of cells in each bottle is (0.8-1) × 10⁶Adding 0.1mL of cross-linking agent into a culture bottle to promote hydrogel to form a jelly-like shape, adding 5mL of serum-free culture medium on the surface of the hydrogel in the culture bottle, placing the culture bottle containing aqueous gel cell suspension in a culture box with the temperature of 36-37 ℃, the volume fraction of carbon dioxide and the saturation humidity for amplification culture for 6-7 days, observing the growth condition of the cells every day, and taking the second-generation and third-generation WJMSCs for the next procedure.

⑤ hypoxia culturing, washing the second generation cell, adding serum-free cell culture medium, and adjusting cell concentration to (0.8-1) × 10⁵10mL of the suspension was added to a cell culture flask, and the total number of cells was (0.8-1) × 10⁶Firstly, placing a cell culture bottle into a carbon dioxide saturated humidity incubator with the volume fraction of 5% at 37 ℃ for culture, placing the cell culture bottle into a hypoxia incubator with the oxygen volume concentration of 5% and the saturated humidity at 37 ℃ for culture for 12 hours after 60% fusion of adherent culture of cells, and washing and entering the next procedure. By the low-oxygen culture, the cell tolerance, activity and viability are improved.

The cells can be used to prepare injection, and can be frozen for use if not used.

⑥ freezing and storing the second or third generation cells, washing, adding into serum-free cell culture medium containing 8-12% DMSO, and mixing to obtain cell with concentration of (1.5-2.5) × 10⁷and/mL, cooling at the speed of 0.5-1.5 ℃/min by using a programmed cooling instrument, and when the temperature is reduced to-80 ℃, putting the cells into liquid nitrogen for freezing storage for resuscitation culture and use when required.

It should be noted that, in the above (a), (b), and (c), the step (c) is not essential, and the cells used for preparing the injection may be derived from the cells subjected to the hypoxic culture in the step (c), or may be cells subjected to the resuscitation culture and the hypoxic culture after the cryopreservation in the step (c). The cells are used for preparing injection after hypoxia culture, and are frozen for standby if not used.

(IV) preparing a mixed stem cell injection for revascularization, which comprises the following specific steps:

respectively adding 3 generations of APC, Flk-1+ cells and WJMSCs cultured in the absence of (low) oxygen into physiological saline, centrifuging at (100-⁷The concentration is that the three kinds of cells are prepared into the following proportion according to the cell number, APC, Flk-1+ cells, WJMSCs 1:40-60:80-120, the suspension of the three kinds of cells is the mixed injection of the stem cells of the blood vessel regeneration, the mixed injection is injected into a medicine tube of the sterile injection, the total cell number in each tube is (1.5-2.5) × 10⁷The volume was adjusted to 2mL with physiological saline.

After safety detection, the angiogenesis stem cell mixed injection liquid mixed by three cells of APC, Flk-1+ cells and WJMSCs is added with human serum albumin, the mass concentration of the human serum albumin is 0.2-0.25 percent, and the angiogenesis stem cell mixed injection liquid is prepared to contain (1.5-2.5) × 10 in every 2mL of human serum albumin/normal saline⁷The number of cells is one packaging unit of injection; sealing, and immediately using, or storing at 4-8 deg.C, and using within 12 hr.

The following are specific examples of the present invention.